LncRNA Information | ||||||
---|---|---|---|---|---|---|
ID | EL1405 | Name | Ube3a-ATS | Aliases | N/A | |
Species | Homo sapiens | Chromosome | N/A | Start site | N/A | |
End site | N/A | Chain | N/A | Exon NO. | N/A | |
Assembly | N/A | Class | N/A | NCBI accession | N/A | |
Ensembl | N/A | Sequence | N/A |
Disease | |||||||||
---|---|---|---|---|---|---|---|---|---|
Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
Angelman syndrome | N/A | N/A | N/A | N/A | ASO treatment achieved specific reduction of Ube3a-ATS and sustained unsilencing of paternal Ube3a in neurons in vitro and in vivo. Partial restoration of UBE3A protein in an Angelman syndrome mouse model ameliorated some cognitive deficits associated with the disease. | 25470045 | LncRNADisease | ||